Last reviewed 2026-04-20 · How we verify

Rybelsus

At a glance

Approved indications

• Diabetes mellitus type 2
• Obesity
• Weight loss

Common side effects

• Nausea
• Abdominal Pain
• Diarrhea
• Decreased Appetite
• Vomiting
• Constipation

Key clinical trials

• Efficacy and Safety of QLG1090 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes (PHASE3)
• GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV (PHASE2)
• Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis (PHASE4)
• Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function (NA)
• The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (PHASE2)
• Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial (PHASE2)
• Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (PHASE2)
• Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Rybelsus CI brief — competitive landscape report
• Rybelsus updates RSS · CI watch RSS
• Pfizer portfolio CI